Audiometric monitoring of cis-platinum ototoxicity.
A prospective study was performed on 37 patients receiving 50 mg/m2 of cis-platinum every 3 to 4 weeks. These patients received a baseline audiogram evaluation and subsequent testing before each dose. Ototoxicity was noted to occur in 46% of the patients during therapy. Fourteen percent of this group showed a hearing loss in the speech frequency range. Four variables were analyzed to determine their correlative value for subsequent ototoxicity: (i) Pretreatment (baseline) audiograms, (ii) cumulative dose in milligrams, (iii) dosage in milligrams per square meter, and (iv) mean serum creatinine. Of these parameters, only a pretreatment abnormal audiogram was shown to have a prognostic value at a level of P = 0.095. Recommendations for audiometric monitoring of this high-risk group are discussed.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001299:Audiometry; D001301:Audiometry, Pure-Tone; D002945:Cisplatin / Q000009:adverse effects*; D003404:Creatinine / Q000097:blood; D004305:Dose-Response Relationship, Drug; D005260:Female; D034381:Hearing Loss / Q000139:chemically induced* / Q000175:diagnosis; D006801:Humans; D008875:Middle Aged; D008991:Monitoring, Physiologic; D011446:Prospective Studies
D003404:Creatinine; D002945:Cisplatin